Antibody-Based Therapies for Peripheral T-Cell Lymphoma

Area of Science:

• Immunotherapy
• Oncology
• Hematology

Background:

• B-cell lymphoma treatments have advanced with antibody therapies, but T-cell lymphomas (PTCL) face challenges like target limitations and heterogeneity.
• Limited effective options exist for PTCL, necessitating novel therapeutic strategies.

Purpose of the Study:

• To review current and emerging antibody-based immunotherapeutic strategies for peripheral T-cell lymphoma (PTCL).
• To discuss monoclonal antibodies (mAbs), bispecific antibodies (BsAs), chimeric antigen receptor T-cell therapy (CAR-T), and antibody-drug conjugates (ADCs) in PTCL treatment.

Main Methods:

• Literature review of antibody-based strategies in PTCL treatment.
• Analysis of advancements in T-cell biology and novel target identification.
• Exploration of four key antibody-based therapeutic areas: mAbs, BsAs, CAR-T, and ADCs.

Main Results:

• Monoclonal antibodies, bispecific antibodies, CAR-T therapy, and antibody-drug conjugates represent evolving treatment modalities for PTCL.
• Recent progress in understanding T-cell biology offers new therapeutic targets.
• Despite challenges, these antibody-based approaches provide emerging hope for PTCL patients.

Conclusions:

• Antibody-based strategies are crucial for advancing PTCL treatment, despite historical challenges.
• Continued research into novel targets and therapies like CAR-T and ADCs is vital.
• Future directions involve overcoming limitations and optimizing these antibody-based treatments for PTCL.